Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Maris

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialStefan Faderl, Meir Wetzler, David Rizzieri, et al.
Targeted Oncology|April 29, 2024
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 StudyMichael Maris, Gilles Salles, Won Seog Kim, et al.
International Journal of Hematology|November 15, 2002
Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseasesGeorge E Georges, Michael Maris, Brenda M Sandmaier, et al.
Cancer|January 18, 2017
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G Berdeja, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialStefan Faderl, Meir Wetzler, David Rizzieri, et al.
Targeted Oncology|April 29, 2024
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 StudyMichael Maris, Gilles Salles, Won Seog Kim, et al.
International Journal of Hematology|November 15, 2002
Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseasesGeorge E Georges, Michael Maris, Brenda M Sandmaier, et al.
Cancer|January 18, 2017
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G Berdeja, et al.
Pageof 5